男生普通话版 下载mp3 女声普通话版 下载mp3 粤语版 下载mp3 西南方言版 下载mp3 东北话版 下载mp3 上海话版 下载mp3 今日优选 美联储连续第三次维持利率不变 知情人士：特朗普政府拟取消拜登时代的AI芯片限制 印度：如果巴基斯坦对袭击做出回应，印度也将做出回应 欧洲委员会：将于周四宣布关于应对美关税的下一步反制措施的准备工作 外交部：会谈是应美方请求举行的 中国央行连续第六个月增持黄金 证监会印发《推动公募基金高质量发展行动方案》 A股4月新开户192万户，同比增长31% 市场盘点 周三，因美联储按兵不动，以及鲍威尔重申愿意等前景更明朗再行动，美元指数走强，最终收涨0.47%，报99.86。基准的10年期美债收益率收报4.2740%； 对货币政策更敏感的两年期美债收益率收报3.7870%。 因市场对贸易谈判持乐观态度，加上美元走强，现货黄金日内大跌逾60美元，最终收跌2.12%，报3364.07美元/盎司；现货白银收跌2.28%，报32.43美元/盎 司。 因伊朗与美国达成核协议的希望缓解了市场对原油供应减少的忧虑，WTI原油最终收跌1.81%，报57.91美元/桶；布伦特原油收跌1.76 ...

Core Insights - JD Health and China National Pharmaceutical Group have signed a strategic cooperation agreement to enhance the accessibility of quality medical resources and promote health technology [1][2] - The partnership aims to launch innovative pharmaceutical products, including the first domestically approved tolvaptan patch and a sodium loxoprofen gel patch, through JD Health's online channels [1][2] Group 1: Strategic Partnership - JD Health and China National Pharmaceutical Group will collaborate in disease knowledge dissemination and new product launches [1] - The partnership is expected to leverage JD Health's online platform to improve public access to healthcare services [1][2] Group 2: Product Launches - JD Health will exclusively distribute the 2mg tolvaptan patch online, which is designed to alleviate symptoms of bronchial asthma and other obstructive airway diseases [1] - Another product, sodium loxoprofen gel patch, is the first in China to complete phase III clinical trials and is aimed at treating inflammation and pain from osteoarthritis and muscle injuries [1] Group 3: Market Trends - JD Health is positioned as the leading online health consumption platform, with e-commerce channels projected to account for 12.9% of the pharmaceutical retail market by 2024 [2] - The company employs a comprehensive "B2C + O2O + offline store" model to integrate supply chain, logistics, and medical resources effectively [2] Group 4: Future Collaboration - The partnership will expand to cover various disease areas, including oncology, rheumatology, and cardiovascular health, utilizing JD Health's internet hospital resources [2] - Both companies aim to transform authoritative medical knowledge into accessible content for the public, enhancing health education and chronic disease management [2]

"如果再出现这样的机会，我会在一秒钟内做出反应，以低于市场平均市盈率水平的价格，一篮子的买 入一批大型制药股。" 对于医药股，股神巴菲特很坦诚，因为他很难去做选择，所以错过了一大批投资机会。5月3日，在今年 的股东大会上，巴菲特对于医药股更是鲜有提及。 不过，股神没有青睐的行业，并不是说没有机会。就在今年以来，A股、港股的医药板块悄然崛起，目 前累计涨幅已经超过火爆的机器人板块，而创新药板块更是成为这波上涨的"急先锋"。 来自WIND资讯的统计数据显示，截至4月30日，在港股上市的恒生生物科技指数(HSHKBIO)今年以来 表现突出，同期累计涨幅达到32.83%,而同期恒生科技指数的涨幅仅有17.37%。 更为引人关注的是，这波行情已经蔓延到医药股，就连A股相关主题基金也受益匪浅，多只医药主题基 金今年以来涨幅已经超过40%。 (1)看点一：业绩领跑 如果说今年表现最火的板块，那大多数人的第一反应，肯定是科技板块，尤其是机器人板块。不过，现 在又有了新变化。 上述统计显示，就在港股板块中，随着生物科技指数的大涨，一个不容忽视的事实是，主要投资医药尤 其是创新药板块的生物科技指数，已经大幅跑赢了恒生科技指数，而 ...

Core Viewpoint - The Hong Kong stock market opened higher due to a combination of central bank policies and upcoming high-level US-China trade talks, but the gains were limited as major indices showed mixed performance by the end of the trading day [1] Group 1: Market Performance - The Hang Seng Index closed up 0.13% or 29.17 points at 22,691.88 points, with a total trading volume of 240.05 billion HKD [1] - The Hang Seng China Enterprises Index fell by 0.23% to 8,242.25 points, while the Hang Seng Tech Index decreased by 0.75% to 5,200.04 points [1] Group 2: Blue-Chip Stocks - Link REIT (00823) led blue-chip stocks with a rise of 6.68% to 39.95 HKD, contributing 10.74 points to the Hang Seng Index [2] - Other notable blue-chip performances included Zhongsheng Group (00881) up 4.8% and AIA Group (01299) up 2.92%, while Mengniu Dairy (02319) and China Biologic Products (01177) saw declines of 3.6% and 3.04% respectively [2] Group 3: Sector Highlights - Military stocks performed well, with AVIC Aircraft (02357) rising 6.35% and China Shipbuilding Industry (00317) up 5.97%, driven by escalating tensions in the India-Pakistan region [3] - The Macau gaming sector continued its upward trend, with SJM Holdings (00200) increasing by 4.73% and Sands China (01928) by 2.67%, supported by strong visitor numbers during the May Day holiday [4] - Financial stocks generally rose, with China Construction Bank (00939) up 2.02% and China Life Insurance (02628) up 1.51% [4] Group 4: Policy Impact - The People's Bank of China announced a series of monetary policy measures, including a 0.5 percentage point reserve requirement ratio cut and a reduction in policy interest rates by 0.1 percentage points, aimed at stabilizing the market [5] - The housing loan interest rate was also lowered by 0.25 percentage points, which is expected to positively impact the real estate sector [6] Group 5: Notable Stock Movements - Boleton (01333) debuted with a significant increase of 38.33% to 24.9 HKD, focusing on electric engineering machinery [8] - Yuan Da Pharmaceutical (00512) rose 13.36% to 6.79 HKD following successful clinical trial results for a new drug [9] - Country Garden Services (06098) fell 5.55% to 6.64 HKD due to a financing arrangement involving a loan from its major shareholder [10]

Group 1 - The core viewpoint of the articles is the strategic partnership between China National Pharmaceutical Group and JD Health, aimed at enhancing the supply chain, retail channels, and innovative marketing models in the pharmaceutical sector [1][2] - The collaboration is seen as a key initiative to bridge the "last mile" in drug accessibility, leveraging digital healthcare to eliminate information barriers and geographical limitations, allowing patients to access quality medications more quickly [1] - The partnership will expand to cover various disease areas including oncology, rheumatology, surgery/pain management, liver disease, respiratory, cardiovascular, and endocrine disorders, utilizing resources from JD Health's internet hospital and expert doctors [1] Group 2 - China National Pharmaceutical Group launched two new products: Loxoprofen Sodium Gel Patch (brand name: Deshu Ping) and Torasemide Patch (brand name: Deruituo), with over 70 innovative drugs currently in development and plans to launch more than 50 innovative drugs in the next decade [2] - The collaboration will focus on three strategic directions: creating a "drug zone for all treatment areas," establishing an "innovative drug digital incubation platform," and innovating a comprehensive health management model that shifts from "passive treatment" to "proactive health management" [2] - The aim is to enhance patient health levels through a patient-centered service model, integrating medical education, medication guidance, and patient recruitment systems [2]

金十数据5月7日讯，港股今日高开低走，反覆向下。恒指高开507点报23169点，开市已重上50天线，升 幅曾扩大至534点高见23197点，创4月2日后一个月高位，但随后买盘未有跟进，大市升幅震荡收窄。午 后一度回顺，但尾盘抛压加重，涨幅再度回吐。截至收盘，恒指收涨0.13%；科指收跌0.75%，恒指大 市成交额2400.5亿元。盘面上，内房、服装、影视娱乐股走强，纸业、体育用品股回暖，军工股强势领 涨；生物医药、电讯设备、玩具消闲股走低，公共运输、非酒精饮料、医药外包概念股回调，汽车股再 度走弱。个股方面，领展房地产基金(00823.HK)涨超6.6%，中升控股(00881.HK)涨近5%，友邦保险 (01299.HK)涨近3%，理想汽车(02015.HK)、携程集团(09961.HK)、中国石油股份(00857.HK)均涨超 2%；药明生物(02269.HK)跌超6.6%，蒙牛乳业(02319.HK)、中国生物制药(01177.HK)均跌超3%，小米 集团(01810.HK)跌近3%。 港股收评：恒指收涨0.13% 大市受制于50日线 ...

Group 1 - The Hang Seng Index closed up by 0.13%, while the Tech Index fell by 0.75% [1] - Zhongsheng Holdings (00881.HK) rose nearly 5%, and AIA Group (01299.HK) increased by almost 3% [1] - WuXi Biologics (02269.HK) dropped nearly 6.7%, while Mengniu Dairy (02319.HK) and China National Pharmaceutical Group (01177.HK) both fell over 3% [1]

Market Performance - As of May 7, 2025, the Hang Seng Healthcare Index (HSHCI) decreased by 3.02%, with mixed performance among constituent stocks [3] - Leading gainers included Yuan Da Pharmaceutical (00512) up 12.52%, Shanghai Pharmaceuticals (02607) up 2.23%, and China Traditional Chinese Medicine (00570) up 1.96% [3] - Major decliners were Sangfor Technologies (01530) down 8.40%, Ascentage Pharma-B (06855) down 8.13%, and BeiGene (06160) down 7.70% [3] - The Hang Seng Healthcare ETF (513060) fell by 2.65%, closing at 0.48 yuan, with an active trading volume of 1.096 billion yuan [3] Investment Insights - Dongfang Securities noted that the continuous release of diagnostic and treatment demand, along with the commercialization of domestic innovative products, is leading to marginal improvements in certain sectors [3] - The firm believes that the upcoming quarters will see confirmed industry growth due to supply-side innovations driving rapid demand growth, suggesting that now is an excellent time to allocate resources to the healthcare sector [3] Future Investment Trends - Guolian Minsheng Securities anticipates that overseas expansion of innovative drugs, AI integration, and left-side asset valuation recovery will be key investment themes in the pharmaceutical sector for 2025 [4] - Recommendations include traditional pharmaceutical companies with manageable risks and reasonable valuations, as well as innovative drug companies with strong R&D foundations and competitive products for overseas markets [4] ETF Performance Metrics - As of May 6, 2025, the Hang Seng Healthcare ETF has seen a 28.71% increase in net value over the past year [5] - The ETF's highest monthly return since inception was 28.34%, with an average monthly return of 6.79% [5] - The ETF's management fee is 0.50%, and the tracking error is 0.041%, indicating high tracking precision compared to similar funds [5] Top Holdings - The top ten weighted stocks in the Hang Seng Healthcare Index account for 57.17% of the index, with major players including BeiGene (06160) and WuXi Biologics (02269) [6][8]

市场期待DeepSeek-R2大模型5月发布。年初DeepSeek爆火带动AI概念扩散至创新药。据了解，目前AI 算法在临床前药物发现阶段已经有深入应用，海外头部临床CRO公司在临床试验中已经布局AI多年， 完全由AI研发的新药有望在1～2年内成功上市。而且，AI可以赋能药物研发的全流程，相关的企业有 望通过AI技术缩短研发周期、降低成本、提高效率。 大而全：创新药ETF（159992）跟踪创新药指数，该指数布局创新药产业链龙头企业，既汇聚全球CXO 龙头企业，又包含国内仿创药企龙头，有望同时受益于AI赋能创新药、国产创新药出海、针对高价创 新药的医保丙类目录出台等。 信达证券认为，创新药板块在2025年第二季度展现出较高的投资价值，这主要得益于一系列积极的行业 动态和政策支持。首先，随着医保谈判、医保丙类目录落地预期以及多个重要肿瘤药临床会议等事件的 催化，创新药市场有望迎来新的增长点。其次，随着医疗整顿负面影响的逐步消化，院内市场的恢复将 为创新药的销售提供更稳定的环境。综上所述，创新药板块在多重利好因素的共同作用下，具备较高的 投资吸引力。 相关产品：港股创新药ETF（159567）、创新药ETF（15 ...

Core Viewpoint - The article narrates the inspiring journey of Zang Jianhe, who transformed her struggles into a successful frozen dumpling brand "Wanchai Ferry," achieving annual sales of 6 billion HKD, showcasing her resilience and entrepreneurial spirit [11][24]. Group 1: Background and Early Struggles - Zang Jianhe moved to Hong Kong in the 1970s with only 500 HKD, facing the challenge of raising her two daughters alone after her husband abandoned them [4][14]. - Initially, she worked multiple jobs to afford a small living space, eventually discovering her talent for making dumplings, which became her source of income [17][18]. - Zang started selling dumplings at Wanchai Pier, overcoming her initial hesitations and gaining popularity among customers [11][19]. Group 2: Business Development - In 1985, Zang established her company with the support of a Japanese department store, leading to the creation of the first Wanchai Ferry factory [24]. - The brand expanded its product line from fresh dumplings to frozen dumplings and other items, capturing a significant market share in Hong Kong [26][27]. - Zang's cautious approach in selecting international partners, such as Pillsbury, allowed her to access advanced production technologies and expand into mainland China [28][29]. Group 3: Legacy and Impact - Zang Jianhe's story reflects the challenges of entrepreneurship in the food industry, especially in today's competitive landscape where restaurant lifespans average only 508 days [32]. - Her commitment to quality and customer feedback helped establish Wanchai Ferry as a leading brand, influencing the frozen food sector in China [35][38]. - Zang's legacy continues to inspire future entrepreneurs, highlighting the importance of resilience, innovation, and customer-centric business practices [30][39].